Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (24)	10/5/1999 11:48:00 PM
From: WTDEC	Respond to of 200

Martin, Maybe this will stir some life into this little undervalued gem--- Tuesday October 5, 4:30 pm Eastern Time Company Press Release SOURCE: Genset Genset and Janssen Identify a Novel Candidate Gene Associated with Schizophrenia Reaching a Milestone Towards the Understanding of This Complex CNS Disorder PARIS, Oct. 5 /PRNewswire/ -- Genset (Nasdaq: GENXY; Nouveau Marche: GENSET) announced today that it and the Janssen Research Foundation, a subsidiary of the US pharmaceutical company Johnson & Johnson, reached an important milestone in their schizophrenia research collaboration. Less than two years after receiving a comprehensive collection of clinical samples, Genset successfully identified and delivered to Janssen a novel candidate gene associated with schizophrenia. Financial terms were not disclosed <SNIP>